Posted inGastroenterology Internal Medicine news
Can a Peripheral Opioid Antagonist Break the Cycle of Recurrent Acute Pancreatitis? Insights from the PAMORA-RAP Trial
The PAMORA-RAP trial suggests that naldemedine, a peripherally acting μ-opioid receptor antagonist, may reduce the risk of recurrent acute pancreatitis by nearly 50%, offering a potential first-in-class pharmacological strategy for this high-burden condition.